A number of factors associated with CDKi resistance have been identified via various approaches, such as ORF kinome screening of cells treated with ribociclib and fulvestrant [10], as well as whole-exome sequencing of breast cancer tissues in paired settings of pre-treatment and post-resistance to ER-targeted therapy [15]. Here, ESR1 is linked to breast carcinoma.